International Clinical and Medical Case Reports Journal
Short Communication (ISSN: 2832-5788)

The Vital Role of Personalized Target Cancer Immunotherapy

Nemat Khansari*

Department of Immunology, Tehran University of Medical Sciences, School of Medicine, Iran

Citation: *Nemat Khansari. The Vital Role of Personalized Target Cancer Immunotherapy. Int Clinc Med Case Rep Jour. 2024;3(9):1-6.*

Received Date: 25 September, 2024**; Accepted Date:** 27 September, 2024**; Published Date:** 29 September, 2024

***Corresponding author:** Nemat Khansari, Department of Immunology, Tehran University of Medical Sciences, School of Medicine, Iran

ABSTRACT

Cancer immunotherapy has seen significant advancements, offering more effective and personalized treatments. Emerging technologies, such as artificial intelligence and engineering approaches, have enabled the development of immunotherapies that precisely target individual tumor characteristics, empowering the immune system to combat the disease. This approach is based on the understanding that cancer is not a monolithic disease but encompasses a diverse array of genetic and phenotypic variations. The integration of immunotherapy with targeted therapies has shown promise in improving patient outcomes, particularly in cases where conventional treatments have failed or are less effective. When appropriately targeted, tumor-associated antigens (TAAs)or neoantigens unique to an individual's cancer can elicit a robust immune response. Advances in genomic sequencing technologies have facilitated the identification of these neoantigens, leading to the development of personalized cancer vaccines designed to stimulate the immune system against these unique targets.

Cancer remains a formidable foe, with millions of lives lost each year. However, cancer immunotherapy has experienced remarkable advancements, offering new hope for more effective and personalized treatments. Emerging technologies, such as artificial intelligence and engineering approaches, have paved the way for developing innovative immunotherapies that can precisely target individual tumor characteristics, empowering the immune system to combat this devastating disease.

Personalized targeted cancer immunotherapy has emerged as a transformative approach to treating malignancies, leveraging the unique characteristics of individual tumors and the patient's immune system to enhance therapeutic efficacy. This innovative strategy is predicated on the understanding that cancer is not a monolithic disease; rather, it encompasses a diverse array of genetic and phenotypic variations that necessitate tailored treatment regimens.

The integration of immunotherapy with targeted therapies has shown promise in improving patient outcomes, particularly in cases where conventional treatments have failed or are less effective [1,2]. One of the cornerstones of personalized cancer immunotherapy is identifying and targeting specific tumor-associated antigens (TAAs) or neoantigens unique to an individual's cancer. These antigens can elicit a robust immune response when appropriately targeted, allowing for the selective destruction of cancer cells while sparing normal tissues. Advances in genomic sequencing technologies have facilitated the identification of these neoantigens, which arise from tumor-specific mutations. This has led to the development of personalized cancer vaccines designed to stimulate the immune system against these unique targets [3,4]. For instance, neoantigen-based vaccines have shown promise in clinical trials, demonstrating the potential for durable responses in patients with advanced cancers [5,6]

.

The tumor microenvironment (TME) plays a critical role in the efficacy of cancer immunotherapy. The TME comprises various immune cells, stromal cells, and extracellular matrix components that can promote or inhibit anti-tumor immunity. Recent research has highlighted the importance of targeting the TME to enhance the effectiveness of immunotherapeutic agents. Modulating the TME can improve immune cell infiltration and activity, augmenting the overall anti-tumor response [7,8]. For example, strategies involving immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, have been shown to reinvigorate exhausted T cells within the TME, leading to improved clinical outcomes in various cancer types [9,10]. Another significant advancement in personalized cancer immunotherapy is chimeric antigen receptor (CAR) T-cell therapy. This approach involves engineering a patient's T cells to express receptors that specifically recognize and bind to tumor antigens. Once reintroduced into the patient, these CAR T cells can proliferate and mount a targeted attack against cancer cells. The success of CAR T-cell therapy in hematological malignancies has paved the way for its application in solid tumors. However, challenges remain in identifying suitable targets and overcoming the immunosuppressive TME [11,12]. Nanotechnology has also emerged as a powerful tool in personalized cancer immunotherapy.

Targeted nanoparticles can be designed to deliver immunotherapeutic agents directly to tumor sites, enhancing drug accumulation while minimizing systemic toxicity. These nanoparticles can be engineered to release their payload in response to specific stimuli within the TME, thereby improving the precision of treatment [13,14]. For instance, studies have demonstrated that combining nanoparticles with immune checkpoint inhibitors can enhance therapeutic efficacy and overcome resistance mechanisms [15,16]. Furthermore, exploring combination therapies that integrate immunotherapy with targeted therapies has gained traction. Such strategies aim to exploit the synergistic effects of different modalities to enhance anti-tumor responses. For example, combining immune checkpoint inhibitors with targeted therapies that inhibit oncogenic signaling pathways has shown promise in preclinical models and early-phase clinical trials [17,18]. This approach addresses the heterogeneity of tumors and aims to mitigate the development of resistance, a common challenge in cancer treatment.

Despite the significant advancements in personalized, targeted cancer immunotherapy, several challenges remain. The complexity of tumor biology, the dynamic nature of the immune response, and the potential for immune-related adverse events necessitate ongoing research to refine these therapeutic strategies. Identifying reliable biomarkers to predict response to immunotherapy is crucial for optimizing treatment selection and improving patient outcomes [19,20]. Additionally, addressing disparities in access to these innovative therapies is essential to ensure that all patients benefit from advancements in cancer treatment [21,22].

CONCLUSION

Personalized, targeted cancer immunotherapy represents a paradigm shift in oncology, offering the potential for more effective and tailored treatment options for patients. This approach aims to improve clinical outcomes and enhance the quality of life for individuals battling cancer by harnessing the immune system's power and integrating advanced technologies. Continued research and collaboration among scientists, clinicians, and industry stakeholders will be vital in overcoming existing challenges and realizing the full potential of personalized cancer immunotherapy.

REFERENCES

1. Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. Journal for Immunotherapy of Cancer 2018;6(1).

2. Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduction and Targeted Therapy 2021;6(1).

3. Wang Y, Zhang X, Chen G, Shao M. Clinical research progress of telomerase targeted cancer immunotherapy: a literature review. Translational Cancer Research 2024;13(7):3904-3921.

4. Yang M, Olaoba OT, Zhang C, Kimchi ET, Staveley-O'Carroll KF, Li G. Cancer immunotherapy and delivery system: an update. Pharmaceutics 2022;14(8):1630.

5. Lei Y, Zhang E, Bai L, Li Y. Autophagy in cancer immunotherapy. Cells 2022;11(19):2996.

6. Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduction and Targeted Therapy 2021;6(1).

7. Zhang W, Liu Q, Zhou T. Advancements and future directions of immunotherapy in cancer treatment. Journal of Innovations in Medical Research 2023;2(10):73-79.

8. Effer B, Perez I, Ulloa D, Mayer C, Muñoz, F, Bustos D, et al. Therapeutic targets of monoclonal antibodies used in the treatment of cancer: current and emerging. Biomedicines 2023;11(7): 2086.

9. Sun Q, Bai X, Sofias AM, Meel Rvd, Ruiz J, Storm G, et al. Cancer nanomedicine meets immunotherapy: opportunities and challenges. Acta Pharmacologica Sinica 2020;41(7): 954-958.

10. Qixin J, Rushan L, Shuning Z, Xinya W, Shan X. Recent progress of nanotargeted immunotherapy for breast cancer. Medical Research Frontiers 2023.

11. Doroudian M, Zanganeh S, Abbasgholinejad E, Donnelly SC. Nanomedicine in lung cancer immunotherapy. Frontiers in Bioengineering and Biotechnology 2023;11.

12. Wu P, Han JH, Gong Y, Liu C, Han Y, Xie N. Nanoparticle-based drug delivery systems targeting tumor microenvironment for cancer immunotherapy resistance: current advances and applications. Pharmaceutics 2022;14(10):1990.

13. Barbari C, Fontaine T, Parajuli P, Lamichhane N, Jakubski S, Lamichhane P, et al. Immunotherapies and combination strategies for immuno-oncology. International Journal of Molecular Sciences 2020;21(14):5009.

14. Cheng L, Yu J, Hao T, Wang W, Wei M, Li G. Advances in polymeric micelles: responsive and targeting approaches for cancer immunotherapy in the tumor microenvironment. Pharmaceutics 2023;15(11):2622.

15. Debele TA, Yeh CF, Su W. Cancer immunotherapy and application of nanoparticles in cancers immunotherapy as the delivery of immunotherapeutic agents and as the immunomodulators. Cancers 2020;12(12):3773.

16. Chen W, Hu Z, Guo Z. Targeting cd24 in cancer immunotherapy. Biomedicines 2023;11(12):3159.

17. Miyazato K, Hayakawa Y. Pharmacological targeting of natural killer cells for cancer immunotherapy. Cancer Science 2020;111(6):1869-1875.

18. Ai H, Yang H, Li L, Ma J, Liu K, Li Z. Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers. Frontiers in Immunology 2023:14.

19. Jenkins RW, Thummalapalli R, Carter J, Cañadas I, Barbie DA. Molecular and genomic determinants of response to immune checkpoint inhibition in cancer. Annual Review of Medicine 2018;69(1): 333-347.

20. Cai H, Li M, Deng R, Wang M, Shi Y. Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy. Biomarker Research 2022;10(1).

21. Lou K, Feng S, Zhang G, Zou J, Zou X. Prevention and treatment of side effects of immunotherapy for bladder cancer. Frontiers in Oncology 2022;12.

22. Zhang, Zhang C, Fu Z, Gao Q. Immune modulatory effects of molecularly targeted therapy and its repurposed usage in cancer immunotherapy. Pharmaceutics 2022;14(9):1768.